Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Heritage Sampling Program Reports Highest Gold Assay Ever at 2,330g/t Gold (click to learn more) TINGO RELEASES RESULTS FOR THIRD QUARTER OF 2022 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Holding SA RLFTF

Healthcare Biotechnology
Relief Therapeutics Holding SA is a based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.


Recent & Breaking News (OTCQB:RLFTF)

Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration

Accesswire June 2, 2021

NRx Pharmaceuticals Announces Positive Results for ZYESAMI(TM) (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure

PR Newswire June 1, 2021

Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer

Accesswire May 28, 2021

Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG

Accesswire May 27, 2021

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA

GlobeNewswire May 25, 2021

Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders

Accesswire May 18, 2021

Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

Accesswire May 17, 2021

Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR

Accesswire May 4, 2021

Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome

Accesswire April 22, 2021

Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.

Accesswire April 19, 2021

Relief Reports 2020 Financial Results and Provides Business Update

Accesswire April 15, 2021

Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant

Accesswire April 7, 2021

NeuroRx Announces Zyesami(TM) (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

PR Newswire April 6, 2021

Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil)

Accesswire March 30, 2021

/C O R R E C T I O N -- NeuroRx/

PR Newswire March 29, 2021

NeuroRx Announces ZYESAMI(TM) (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

PR Newswire March 29, 2021

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

GlobeNewswire March 22, 2021

Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals

Accesswire March 15, 2021

Relief Announces CHF 10 Million Private Placement

Accesswire March 12, 2021

Relief Increases Issued Share Capital with Creation of Treasury Shares

Accesswire March 8, 2021